Whelan P - Search Results

1

Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer.

Cooper EH, Whelan P, Purves D. Cooper EH, et al. Among authors: whelan p. Prostate. 1994 Nov;25(5):236-42. doi: 10.1002/pros.2990250503. Prostate. 1994. PMID: 7526352

2

Tumor markers in prostate cancer.

Cooper EH, Robinson MR, Whelan P, Ferro MA. Cooper EH, et al. Among authors: whelan p. Cancer. 1992 Jul 1;70(1 Suppl):225-9. doi: 10.1002/1097-0142(19920701)70:1+<225::aid-cncr2820701309>3.0.co;2-v. Cancer. 1992. PMID: 1376192 Review.

3

An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostate.

Siddall JK, Cooper EH, Newling DW, Robinson MR, Whelan P. Siddall JK, et al. Among authors: whelan p. Eur Urol. 1986;12(2):123-30. doi: 10.1159/000472596. Eur Urol. 1986. PMID: 2420600

4

Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.

Spencer JA, Chng WJ, Hudson E, Boon AP, Whelan P. Spencer JA, et al. Among authors: whelan p. Br J Radiol. 1998 Nov;71(851):1130-5. doi: 10.1259/bjr.71.851.10434906. Br J Radiol. 1998. PMID: 10434906 Clinical Trial.

5

The use of real-time reverse transcription-PCR for prostate-specific antigen mRNA to discriminate between blood samples from healthy volunteers and from patients with metastatic prostate cancer.

Patel K, Whelan PJ, Prescott S, Brownhill SC, Johnston CF, Selby PJ, Burchill SA. Patel K, et al. Clin Cancer Res. 2004 Nov 15;10(22):7511-9. doi: 10.1158/1078-0432.CCR-04-0166. Clin Cancer Res. 2004. PMID: 15569981

6

Does failure of single hormone therapy delineate hormone refractoriness for prostate cancer?

Kotwal S, Whelan P. Kotwal S, et al. Among authors: whelan p. Scand J Urol Nephrol. 2008;42(2):116-20. doi: 10.1080/00365590701571548. Scand J Urol Nephrol. 2008. PMID: 17907049 Clinical Trial.

7

Interactions of retinoic acid and androgens in human prostatic tissue.

Jutley JK, Reaney S, Kelleher J, Whelan P. Jutley JK, et al. Among authors: whelan p. Prostate. 1990;16(4):299-304. doi: 10.1002/pros.2990160404. Prostate. 1990. PMID: 1695368

8

Cytosolic retinoic acid-binding protein in human prostatic dysplasia and neoplasia.

Jutley JK, Kelleher J, Whelan P, Mikel J. Jutley JK, et al. Among authors: whelan p. Prostate. 1987;11(2):127-32. doi: 10.1002/pros.2990110204. Prostate. 1987. PMID: 2444952

9

Changing trends in prostatic cancer.

Murphy M, Johnston C, Whelan P, Rider L, Lloyd SN. Murphy M, et al. Among authors: whelan p. BJU Int. 1999 May;83(7):786-91. doi: 10.1046/j.1464-410x.1999.00047.x. BJU Int. 1999. PMID: 10368197

10

Use of intravenous fosfestrol tetrasodium (Honvan) infusion in treatment of symptomatic advanced prostate cancer.

Williams AR, Whelan P. Williams AR, et al. Among authors: whelan p. Prostate Cancer Prostatic Dis. 1998 Jun;1(4):204-207. doi: 10.1038/sj.pcan.4500235. Prostate Cancer Prostatic Dis. 1998. PMID: 12496896

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

385 results

Search Page